Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs Victoria's Secret & Co (VSXY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs Victoria's Secret & Co — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $295.33 (market cap $8.04B), while Victoria's Secret & Co trades at $82.67 (market cap $6.51B). The key difference: Bio-Rad Laboratories, Inc. Class A Common Stock is the larger of the two by market cap, and Victoria's Secret & Co is trading nearer its 52-week high, Bio-Rad Laboratories, Inc. Class A Common Stock nearer its low. Which is the better fit depends on your goals.
| BIO | VSXY | |
|---|---|---|
Market Cap | $8.04B | $6.51B |
Sector | Health | Consumer Cyclical |
52-Week High | $339.75 | $88.50 |
52-Week Low | $241.71 | $17.70 |
Enterprise Value | $7.85B | $9.16B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BIO trades at $297.58, up 0.5% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $305. The stock shows strong profitability with a 51.87% gross margin and positive net income of $760M in 2025, though recent quarters have seen EPS misses. Cash flow from operations remains robust at $532M, supporting financial stability.
Outlook is cautiously optimistic with analyst support, but risks include earnings volatility and high P/E valuation. The company's return to profitability and solid balance sheet provide a foundation for growth, though investors should monitor execution against future earnings expectations and competitive pressures in the biotech sector.
Victoria's Secret (VSXY) trades at $78.98, up 0.79% on the day, with a bullish technical signal and strong analyst support. Recent earnings beats and international growth momentum, particularly a 44.9% surge in Q1 2026 international sales, highlight operational improvements. The stock shows recovering profitability with a net income margin of 3.12% and robust ROE of 29.41%, though valuation metrics like a P/E of 31.47 suggest premium pricing relative to earnings.
The outlook remains positive with a consensus price target of $88.56 implying 12% upside, driven by innovation and global expansion. Risks include competitive pressures and reliance on margin recovery. Institutional sentiment is favorable with no sell ratings, but investors should monitor execution on growth initiatives and macroeconomic impacts on consumer spending.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About Victoria's Secret & Co
Victoria's Secret & Co is a specialty retailer of lingerie, pajamas, and beauty products with prestige fragrances and body care. It serves customers at its Lingerie and Beauty stores around the globe and online enabling them to shop the brand anywhere and anytime.
Read more on VSXY →
